

FIG. 1

BEST AVAILABLE COPY

EXAMPLE1. PT (PHENYTOIN) NANOPARTICLES




FIG. 2A




FIG. 2B

EXAMPLE2. IM (INDOMETHACINE) NANOPARTICLES




FIG. 3A




FIG. 3B

EXAMPLE1: PHENYTOIN (BEFORE PLD TREATMENT)




FIG. 4A

EXAMPLE1: PHENYTOIN (AFTER PLD TREATMENT)




FIG. 4B

EXAMPLE2: INDOMETHACINE (BEFORE PLD TREATMENT)




FIG. 5A

EXAMPLE2: INDOMETHACINE (AFTER PLD TREATMENT)




FIG. 5B

EXAMPLE3: ETHENZAMIDE (BEFORE PLD TREATMENT)




FIG. 6A

EXAMPLE3: ETHENZAMIDE (AFTER PLD TREATMENT)




FIG. 6B

BEST AVAILABLE COPY




FIG. 7

BEST AVAILABLE COPY

BSA-IM COMPOSITE PARTICLES (BSA:IM=9:1)




FIG. 8A

BSA-IM COMPOSITE PARTICLES (BSA:IM=9:1)




FIG. 8B




FIG. 9